Apex Biotechnology (Taiwan) Today
| 1733 Stock | TWD 33.85 0.20 0.59% |
PerformanceSolid
| Odds Of DistressLow
|
Apex Biotechnology is selling for under 33.85 as of the 24th of March 2025; that is 0.59% increase since the beginning of the trading day. The stock's lowest day price was 33.8. Apex Biotechnology has less than a 9 % chance of experiencing financial distress in the next few years and had a solid performance during the last 90 days. The performance scores are derived for the period starting the 24th of December 2024 and ending today, the 24th of March 2025. Click here to learn more.
Apex Biotechnology Corp. engages in the research, development, manufacture, and sale of medical devices by using biosensor technology worldwide. Apex Biotechnology Corp. was founded in 1997 and is headquartered in Hsinchu, Taiwan. APEX BIOTECHNOLOGY operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange.. The company has 99.95 M outstanding shares. More on Apex Biotechnology Corp
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Apex Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Apex Biotechnology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Apex Biotechnology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Thematic Idea | Biotech (View all Themes) |
| Business Concentration | Biotech, Health Care, Health Care Equipment & Supplies, Biotechnology, Healthcare (View all Sectors) |
Apex Biotechnology Corp (1733) is traded on Taiwan Stock Exchange in Taiwan and employs 17 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.57 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Apex Biotechnology's market, we take the total number of its shares issued and multiply it by Apex Biotechnology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Apex Biotechnology Corp operates under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 99.95 M outstanding shares.
Apex Biotechnology Corp has accumulated about 523.23 M in cash with 179.87 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.25.
Check Apex Biotechnology Probability Of Bankruptcy
Ownership AllocationApex Biotechnology holds a total of 99.95 Million outstanding shares. Apex Biotechnology Corp shows 15.5 percent of its outstanding shares held by insiders and 2.52 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Apex Ownership Details
Apex Biotechnology Corp Risk Profiles
Although Apex Biotechnology's alpha and beta are two of the key measurements used to evaluate Apex Biotechnology's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.8701 | |||
| Semi Deviation | 0.8927 | |||
| Standard Deviation | 1.2 | |||
| Variance | 1.44 |
Apex Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Apex Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
Apex Biotechnology Corporate Management
Elected by the shareholders, the Apex Biotechnology's board of directors comprises two types of representatives: Apex Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Apex. The board's role is to monitor Apex Biotechnology's management team and ensure that shareholders' interests are well served. Apex Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Apex Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ben Shen | VP Sales | Profile | |
| Ying Zhu | F Head | Profile | |
| Meng Yang | VP GM | Profile | |
| Thomas Shen | CEO Chairman | Profile | |
| James Chu | Chief Officer | Profile | |
| Chun Wu | VP Spokesman | Profile |
Additional Tools for Apex Stock Analysis
When running Apex Biotechnology's price analysis, check to measure Apex Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apex Biotechnology is operating at the current time. Most of Apex Biotechnology's value examination focuses on studying past and present price action to predict the probability of Apex Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apex Biotechnology's price. Additionally, you may evaluate how the addition of Apex Biotechnology to your portfolios can decrease your overall portfolio volatility.